Sorafenib: key lessons from over 10 years of experience
Sign Up to like & getrecommendations! Published in 2018 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2019.1559058
Abstract: ABSTRACT Introduction: In 2005, sorafenib was the first targeted therapy approved for advanced renal cell carcinoma (RCC), transforming treatment. In hepatocellular carcinoma (HCC), for more than a decade, sorafenib remained the only approved systemic therapy… read more here.
Keywords: hcc dtc; key lessons; treatment; sorafenib ... See more keywords